D8 Holdings Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DEH research report →
Price Chart
About the company
D8 Holdings Corp. , established in 2020, does not engage in substantial commercial operations. Instead, its primary objective revolves around completing a business combination, which may include a merger, a share exchange, the acquisition of assets or shares, a corporate reorganization, or a similar strategic transaction, with one or more entities.
- IPO
- 2007
- HQ
- Central, HK
Get TickerSpark's AI analysis on DEH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.56B
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -0.14
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -333.19%
- ROIC
- -396.87%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-50,027,000
- Net Income
- $-50,182,000+20.6%
- EPS
- $-8.19+23.7%
- OCF Growth
- +9.8%
- FCF Growth
- +9.8%
- 52W High
- $11.66
- 52W Low
- $9.50
- 50D MA
- $10.03
- 200D MA
- $9.96
- Beta
- 0.00
- RSI (14)
- 83
- Avg Volume
- 476.55K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Vicarious Surgical cut expenses and narrowed losses in Q3, while keeping its design-freeze target for the production-equivalent system at year-end 2026 and shifting to a more aggressive burn-reduction plan.· November 12, 2025
- Total operating expenses fell 35% year over year to $11.5 million, helped by lower R&D, G&A, and sales and marketing spend.
- GAAP net loss improved to $11.1 million, or $1.86 per share, versus $17.1 million, or $2.90 per share, a year ago.
- Management said the company still targets design freeze of the production-equivalent system by year-end 2026, but expects some disruption from outsourcing work.
- The company has already restructured some teams and reduced headcount by about 15% to help preserve cash.
- A new communication plan will start with frequent LinkedIn and IR updates, with PA Consulting helping assess outsourcing options through the end of November.
Vicarious Surgical reported third-quarter 2025 total operating expenses of $11.5 million, down 35% from $17.8 million in the third quarter of 2024. R&D was $8.0 million versus $10.8 million last year, G&A was $3.2 million versus $5.7 million, and sales and marketing was $350,000 versus $1.2 million. GAAP net loss was $11.1 million, or $1.86 per share, compared with a GAAP net loss of $17.1 million, or $2.90 per share, in Q3 2024. Non-GAAP adjusted net loss was $11.3 million, or $1.91 per share, versus $17.0 million, or $2.87 per share. The company ended the quarter with approximately $13.4 million of cash, cash equivalents and short-term investments, and said third-quarter cash burn was approximately $10.5 million. Following quarter-end, it completed a registered direct offering that added approximately $5.2 million in net proceeds, and it reiterated full-year 2025 cash burn of approximately $50 million. Management said it is actively focused on reducing cash burn in 2026 and expects a material reduction, but did not provide more detailed numerical 2026 guidance.
Stephen From said his focus has shifted from assessment to execution: reach design freeze, reduce burn, and improve communication. He emphasized that the company still expects design freeze of the production-equivalent system by year-end 2026, but acknowledged the outsourcing initiative may create some disruption. He also said the company is trying to be more transparent about progress and setbacks, with short posts and videos on LinkedIn and the Investor Relations website starting the next day.
Sarah Romano highlighted a meaningful year-over-year reduction in spending, with operating expenses down to $11.5 million from $17.8 million, driven by lower R&D, G&A, and sales and marketing costs. She said the company ended Q3 with about $13.4 million in cash, cash equivalents and short-term investments, saw roughly $10.5 million of cash burn in the quarter, and expects full-year 2025 cash burn to be about $50 million. She also noted the post-quarter registered direct offering added approximately $5.2 million in net proceeds and that management is actively looking for further ways to bolster the balance sheet and reduce burn in 2026.
Analysts focused on whether outsourcing would delay the timeline to regulatory testing and clinical use, and management said it still expects design freeze toward the end of 2026, though there may be some disruption. Stephen From stressed the plan is not a restart, but an effort to preserve the core build while outsourcing less unique components to improve capital efficiency. Questions also centered on development progress and surgeon testing; management said surgeons are using the system in the company’s OR, including weekly labs, and that suturing time for an IPOM ventral hernia has dropped from an average of 40 minutes to 14 minutes. In response to cash questions, management said PA Consulting’s engagement is short and expected to finish by month-end, the cost was fixed fee, and the company has already completed a small layoff of about 15% of employees to help lower burn.
The call showed real progress on cost discipline: operating expenses, net loss, and headcount are all lower, and management says more reduction is coming. Management also described improving system stability and usability in surgeon testing, including a sizable reduction in suturing time, while reaffirming the year-end 2026 design-freeze target.
The company is still early in its outsourcing plan, and management openly said there could be disruption that may affect timing. Cash remains limited at $13.4 million at quarter-end, third-quarter burn was about $10.5 million, and the company is still dependent on additional financing and further burn reduction to reach design freeze.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 38.0%
- Shares Outstanding
- 134.62M
- Float Shares
- 51.19M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 14, 20 | LANGHAMMER FRED | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DEH coverage
Recent articles, reports, and earnings notes.
No research on DEH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DEH report →SPAC Watch: Will This Be the Next Intuitive Surgical?
fool.com · May 20
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of D8 Holdings Corp. - DEH
prnewswire.com · Apr 20
Vicarious Surgical Inc. and D8 Holdings Corp. Announce Definitive Business Combination Agreement
businesswire.com · Apr 15
Vicarious Surgical Inc. and D8 Holdings Corp. Announce Definitive Business Combination Agreement
businesswire.com · Apr 15
D8 Holdings Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 4, 2020
businesswire.com · Sep 1
D8 Holdings Corp. Completes $300 Million Initial Public Offering
businesswire.com · Jul 17
D8 Holdings Corp. Announces Pricing of Upsized $300 Million Initial Public Offering
businesswire.com · Jul 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.